Stock ENTA ENANTA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Enanta Pharmaceuticals, Inc.

Equities

ENTA

US29251M1062

Real-time Estimate Cboe BZX
Other stock markets
 03:21:17 2024-06-10 pm EDT 		5-day change 1st Jan Change
12.82 USD -0.66% Intraday chart for Enanta Pharmaceuticals, Inc. +3.47% +36.13%
May. 07 JMP Securities Adjusts Enanta Pharmaceuticals Price Target to $22 From $23, Maintains Market Outperform Rating MT
May. 06 Transcript : Enanta Pharmaceuticals, Inc., Q2 2024 Earnings Call, May 06, 2024

Evolution of the average Target Price on Enanta Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

03ccd19caaf985ad18b653bf1b4.Op3ZApAUOxdooBVIc6UWBDykRKfBC4qSKoOn5orCY90.De6uRqEjblYY-kYjOJRATUTUM82NQ9DFROLCr8KzIK9X9bNK0SV2VALjQA~69f15049f283d0d038621beeca3a6647

Analyst Recommendations on Enanta Pharmaceuticals, Inc.

JMP Securities Adjusts Enanta Pharmaceuticals Price Target to $22 From $23, Maintains Market Outperform Rating MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $21 From $25, Maintains Perform Rating MT
HC Wainwright Cuts Enanta Pharmaceuticals' Price Target to $28 From $30, Maintains Buy Rating MT
HC Wainwright Adjusts Enanta Pharmaceuticals Price Target to $30 From $48, Maintains Buy Rating MT
Enanta Pharmaceuticals Receives Speculative Risk Qualifier on Sector Perform Rating From RBC, Price Target Cut to $15 From $25 MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $25 From $30, Maintains Perform Rating MT
JMP Securities Lowers Price Target on Enanta Pharmaceuticals to $42 From $65, Maintains Market Outperform Rating MT
Jefferies Downgrades Enanta Pharmaceuticals to Hold From Buy, Adjusts Price Target to $18 From $49 MT
RBC Cuts Enanta Pharmaceuticals' Price Target to $25 From $33, Keeps Sector Perform Rating MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $30 From $50, Maintains Perform Rating MT
JMP Securities Adjusts Price Target on Enanta Pharmaceuticals to $65 From $82, Keeps Market Outperform Rating MT
HC Wainwright Adjusts Enanta Pharmaceuticals' Price Target to $48 From $68, Keeps Buy Rating MT
JMP Securities Adjusts Enanta Pharmaceuticals' Price Target to $65 From $82, Keeps Market Outperform Rating MT
RBC Cuts Price Target on Enanta Pharmaceuticals to $33 From $48, Maintains Sector Perform Rating MT
RBC Capital Adjusts Enanta Pharmaceuticals Price Target to $48 From $54, Maintains Sector Perform Rating MT
RBC Lifts Price Target on Enanta Pharmaceuticals to $54 From $52, Maintains Sector Perform Rating MT
JPMorgan Adjusts Enanta Pharmaceuticals Price Target to $60 From $74, Maintains Neutral Rating MT
RBC Raises Enanta Pharmaceuticals' Price Target $52 From $49, Maintains Sector Perform Rating MT
SVB Securities Adjusts Enanta Pharmaceuticals' Price Target to $49 From $50, Keeps Market Perform Rating MT
HC Wainwright Initiates Enanta Pharmaceuticals With Buy Rating, Sets $56 Price Target MT
RBC Cuts Price Target on Enanta Pharmaceuticals to $54 From $65, Maintains Sector Perform Rating MT
RBC Trims Price Target on Enanta Pharmaceuticals to $65 From $66, Maintains Sector Perform Rating MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $59 From $53, Maintains Perform Rating MT
JMP Securities Raises Enanta Pharmaceuticals' Price Target to $137 From $103, Maintains Market Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
12.91 USD
Average target price
19.75 USD
Spread / Average Target
+52.98%
High Price Target
30 USD
Spread / Highest target
+132.38%
Low Price Target
11 USD
Spread / Lowest Target
-14.79%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Enanta Pharmaceuticals, Inc.

JMP Securities
Oppenheimer
HC Wainwright
RBC Capital Markets
Jefferies & Co.
JPMorgan Chase
SVB Securities LLC
Evercore ISI
Baird
Roth Capital Partners
SVB Leerink
J.P. Morgan Chase

Ratings for Enanta Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ENTA Stock
  4. Consensus Enanta Pharmaceuticals, Inc.